Topics:
Lung Cancer • Melanoma/Skin Cancer • Thoracic Malignancies • Medical Oncology • Immunotherapy • Biologic Therapy/Immunobiology
How do you manage immune-related toxicity from checkpoint inhibitors that is refractory to initial steroid therapy?
What immunosuppressive agents are used and in what order? Does your approach differ depending on the organ involved, e.g. colitis vs. pneumonitis?
Answer from: Medical Oncologist at Academic Institution
Consensus guidelines recommend the use of steroid therapy for immune related adverse events irAE, and fortunately most toxicities (with the exception of endocrinopathies) are reversible. No prospective data exists on the management of irAE, including steroid refractory irAE. In most cases, we use in...
Sign in or Register to read more